Previous 10 | Next 10 |
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Com...
For May 2021, Biofrontera ([[BFRA]] +1.0%) reported prelim revenue from product sales of €2.44M compared to €1.17M in year ago quarter.Out of the total, revenues from product sales in the U.S. increased 174% while Germany revenues dropped 21%; rest of Europe ...
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021. The Companyȁ...
Gainers: Reata Pharmaceuticals (RETA) +20%, LifeMD (LFMD) +13%, Eloxx Pharmaceuticals (ELOX) +10%, Cerecor (CERC) +10%, Biofrontera (BFRA) +7%.Losers: Onconova Therapeutics (ONTX) -23%, Iovance Biotherapeutics (IOVA) -18%,&...
Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 ...
Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...
Biofrontera (BFRA) trades 5.9% higher premarket after estimating April product sales revenue to be ~€2.49M compared to €0.49M in same month last year.Prelim product sales revenues in U.S. increased 447% to €1.82M; Germany revenues rose 208% t...
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021. The Company ...
Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2021 on Tuesday, May 11, 2021...
Biofrontera AG (BFRA) Q4 2020 Earnings Conference Call April 13, 2021 08:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Ludwig Lutter - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Compa...
News, Short Squeeze, Breakout and More Instantly...
Biofrontera AG Company Name:
BFRA Stock Symbol:
NASDAQ Market:
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the N...
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal ...
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. K ...